Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

Moderna has received marketing authorisation from the European Commission for its updated COVID-19 vaccine, Spikevax, which ...